| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IDXX | Common Stock | Options Exercise | $607K | +7.63K | +1.17% | $79.54* | 661K | May 18, 2021 | Direct | |
| transaction | IDXX | Common Stock | Sale | -$4.03M | -7.63K | -1.15% | $528.01 | 654K | May 18, 2021 | Direct | F1 |
| holding | IDXX | Common Stock | 10K | May 18, 2021 | by Ayers Family Trust |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IDXX | Non-Qualified Stock Option (right-to-buy) | Options Exercise | -7.63K | -5.17% | 140K | May 18, 2021 | Common Stock | 7.63K | $79.54 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | Represents the weighted average price of the shares sold ranging from a low of $528.00 to a high of $528.355 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F2 | Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| F3 | Not applicable. |